Identification

Name
Bortezomib
Accession Number
DB00188  (APRD00828, DB07475)
Type
Small Molecule
Groups
Approved, Investigational
Description

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. It is a reversible inhibitor of the 26S proteasome, which is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway. Inhibition of 26S proteasome leads to cell cycle arrest and apoptosis of cancer cells.11 While inhibition of the 26S proteasome is the main mechanism of action, multiple mechanisms may involved in the therapeutic action of bortezomib.5

In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA.6 Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.7

Structure
Thumb
Synonyms
  • [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
  • Bortezomib
  • N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
External IDs
BXCL 101 / BXCL-101 / BXCL101 / LDP 341 / LDP-341 / LDP341 / PS 341 / PS-341 / PS341
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act BortezomibPowder, for solutionIntravenous; SubcutaneousActavis Pharma Company2015-11-17Not applicableCanada
BortezomibPowder, for solution3.5 mgIntravenous; SubcutaneousApotex Corporation2019-03-25Not applicableCanada
BortezomibInjection, powder, lyophilized, for solution1 mg/1mLIntravenousFresenius Kabi USA, LLC2017-11-06Not applicableUs
BortezomibInjection, powder, lyophilized, for solution3.5 mg/1IntravenousDr.Reddy's Laboratories Inc2019-11-01Not applicableUs
Bortezomib for InjectionPowder, for solutionIntravenous; SubcutaneousPfizer Canada UlcNot applicableNot applicableCanada
Bortezomib for InjectionPowder, for solutionIntravenous; SubcutaneousDr Reddy's Laboratories2017-03-21Not applicableCanada
Bortezomib for InjectionPowder, for solutionIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Bortezomib for InjectionPowder, for solutionIntravenous; SubcutaneousTEVA Canada Limited2015-01-06Not applicableCanada
Bortezomib for InjectionPowder, for solutionIntravenous; SubcutaneousMda Inc.Not applicableNot applicableCanada
Bortezomib for InjectionPowder, for solutionIntravenousMda Inc.Not applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bortezomib AccordInjection, powder, for solution3.5 mgIntravenous; SubcutaneousAccord Healthcare Limited2015-07-20Not applicableEu
Bortezomib HospiraInjection, powder, for solution3.5 mgIntravenous; SubcutaneousHospira, Inc.2016-07-22Not applicableEu
Bortezomib SunInjection, powder, for solution3.5 mgIntravenous; SubcutaneousSun Pharmaceutical Industries (Europe) B.V.2016-07-22Not applicableEu
PMS-bortezomibPowder, for solutionIntravenous; SubcutaneousPharmascience Inc2018-06-05Not applicableCanada
Taro-bortezomibPowder, for solutionIntravenous; SubcutaneousTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
69G8BD63PP
CAS number
179324-69-7
Weight
Average: 384.237
Monoisotopic: 384.196885774
Chemical Formula
C19H25BN4O4
InChI Key
GXJABQQUPOEUTA-RDJZCZTQSA-N
InChI
InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
IUPAC Name
[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido)propanamido]butyl]boronic acid
SMILES
CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O

Pharmacology

Indication

Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.8

Associated Conditions
Pharmacodynamics

Bortezomib works to target the ubiquitin-proteasome pathway, an essential molecular pathway that promotes protein degradation and maintains the homeostatic intracellular concentrations of proteins.1 However, there is strong evidence in the literature that the ubiquitin-proteasome pathway is often dysregulated, leading to aberrant pathway signalling. In one study, patient-derived chronic lymphocytic leukemia (CLL) cells contained 3-fold higher levels of chymotrypsin-like proteasome activity than normal lymphocytes, indicating that dysregulation of the ubiquitin-proteasome pathway is implicated in malignant cell transformation.1 By reversibly inhibiting an enzyme involved in the ubiquitin-proteasome pathway, bortezomib prevents the proteasome-mediated proteolysis. Bortezomib exerts a cytotoxic effect on various cancer cell types in vitro. In non-clinical tumour models, including multiple myeloma, bortezomib caused a delay in tumour growth.8

Mechanism of action

Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The active site of the proteasome has chymotrypsin-like, trypsin-like, and postglutamyl peptide hydrolysis activity. The 26S proteasome degrades various proteins critical to cancer cell survival, such as cyclins, tumor suppressors, BCL-2, and cyclin-dependent kinase inhibitors. Inhibition of these degradations sensitizes cells to apoptosis. Bortezomib is a potent inhibitor of 26S proteasome, which sensitizes activity in dividing multiple myeloma and leukemic cells, thus inducing apoptosis. In addition, bortezomib appears to increase the sensitivity of cancer cells to traditional anticancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation).

TargetActionsOrganism
AProteasome subunit beta type-5
inhibitor
Humans
AProteasome subunit beta type-1
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Following intravenous administration of 1 mg/m2 and 1.3 mg/m2 doses, the mean Cmax of bortezomib were 57 and 112 ng/mL, respectively. In a twice-weekly dosing regimen, the Cmax ranged from 67 to 106 ng/mL at the dose of 1 mg/m2 and 89 to 120 ng/mL for the 1.3 mg/m2 dose. In patients with multiple myeloma, the Cmax of bortezomib followig subcutaneous administration was lower than that of intravenously-administered dose; however, the total systemic exposure of the drug was equivalent for both routes of administration.8 There is a wide interpatient variability in plasma concentrations.11

Volume of distribution

The mean distribution volume of bortezomib ranged from approximately 498 to 1884 L/m2 in patients with multiple myeloma receiving a single- or repeat-dose of 1 mg/m2 or 1.3 mg/m2.8

Protein binding

Over the concentration range of 100 to 1000 ng/mL, bortezomib is about 83% bound to human plasma proteins.8

Metabolism

Bortezomib is primarily metabolized by CYP3A4, CYP2C19, and CYP1A2. CYP2D6 and CYP2C9 are also involved in drug metabolism, but to a smaller extent.8 Oxidative deboronation, which involves the removal of boronic acid from the parent compound, is main metabolic pathway. Metabolites of bortezomib are pharmacologically inactive and more than 30 metabolites have been identified in human and animal studies.6

Route of elimination

Bortezomib is eliminated by both renal and hepatic routes.6

Half life

The mean elimination half-life of bortezomib ranged from 40 to 193 hours following a multiple dosing regimen at a 1 mg/m2 dose. The half-life ranged from 76 to 108 hours after multiple dosing of 1.3 mg/m2 bortezomib.8

Clearance

Following the administration of a first dose of 1 mg/m2 and 1.3 mg/m2, the mean mean total body clearances were 102 and 112 L/h, respectively. The clearances were 15 and 32 L/h after the subsequent dose of 1 and 1.3 mg/m2, respectively.8

Toxicity

The Lowest published toxic dose (TDLo) in mouse was 5 mg/kg/14D following intraperitoneal administration of an intermittent dose and 1.6 mg/kg/12D following subcutaneous administration of a continuous dose.10

The therapeutic dose of bortezomib is individualized in each patient to prevent overdose. Fatal outcomes occurred in humans following the administration of more than twice the recommended therapeutic dose of bortezomib. The symptoms from overdose included the acute onset of symptomatic hypotension and thrombocytopenia. As there is no known antidote for bortezomib overdosage, monitoring of vital signs and appropriate supportive care should be initiated when drug overdosage is suspected. In monkeys and dogs, increased heart rate, decreased contractility, hypotension, and death were observed with the intravenous dose as low as two times the recommended clinical dose on a mg/m2 basis. A case of a slight increase in the corrected QT interval leading to death occurred in dog studies.8

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Bortezomib.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Bortezomib.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidineThe metabolism of Bortezomib can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Bortezomib is combined with 2-Methoxyethanol.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Bortezomib.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Bortezomib.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Bortezomib.
6-Deoxyerythronolide BThe metabolism of Bortezomib can be decreased when combined with 6-Deoxyerythronolide B.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Bortezomib.
7-ethyl-10-hydroxycamptothecinThe metabolism of Bortezomib can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of bortezomib.
  • Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of bortezomib.
  • Limit foods and supplements high in flavonoids. Flavonoids may interfere with the therapeutic action of this drug. Foods high in flavonoids include green vegetables, fruits, and green tea.
  • Limit foods and supplements high in vitamin C. Vitamin C may interfere with the therapeutic action of this drug. Foods high in vitamin C include citrus fruits and beverages.

References

Synthesis Reference

Raghavendracharyulu Venkata Palle, Rajasekhar Kadaboina, Veerendeer Murki, Amarendhar Manda, Nageshwar Gunda, Ramaseshagiri Rao Pulla, Mallesha Hanmanthu, Narasimha Naidu Mopidevi, Suresh Kumar Ramdoss, "BORTEZOMIB AND PROCESS FOR PRODUCING SAME." U.S. Patent US20100226597, issued September 09, 2010.

US20100226597
General References
  1. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res. 2003 Dec 15;9(17):6316-25. [PubMed:14695130]
  2. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [PubMed:15953001]
  3. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22. [PubMed:10363983]
  4. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May;2(5):357-62. Epub 2005 Apr 21. [PubMed:15846363]
  5. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. doi: 10.2174/156800911794519752. [PubMed:21247388]
  6. Schwartz R, Davidson T: Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21. [PubMed:15688598]
  7. Guedes RA, Aniceto N, Andrade MAP, Salvador JAR, Guedes RC: Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. Int J Mol Sci. 2019 Oct 25;20(21). pii: ijms20215326. doi: 10.3390/ijms20215326. [PubMed:31731563]
  8. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]
  9. Thermo Fisher Scientific: Bortezomib Safety Data Sheet [Link]
  10. Cayman Chemical: Bortezomib Safety Data Sheet [Link]
  11. BC Cancer: Bortezomib Monograph [Link]
External Links
Human Metabolome Database
HMDB0014334
KEGG Drug
D03150
PubChem Compound
387447
PubChem Substance
46508736
ChemSpider
343402
BindingDB
50069989
RxNav
358258
ChEBI
52717
ChEMBL
CHEMBL325041
ZINC
ZINC000169746649
Therapeutic Targets Database
DAP001318
PharmGKB
PA10252
PDBe Ligand
BO2
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bortezomib
ATC Codes
L01XX32 — Bortezomib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
2f16 / 3mg0 / 4fwd / 4qvl / 4qvm / 4qvn / 4qvp / 4qvq / 4qvv / 4qvw
show 15 more
FDA label
Download (199 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceMultiple Myeloma (MM)1
0CompletedTreatmentAutologous Transplant / Malignant Lymphoma, Stem Cell Type1
0CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias1
0CompletedTreatmentMultiple Myeloma (MM)1
0Not Yet RecruitingHealth Services ResearchBreast Cancer1
0TerminatedTreatmentLymphoma, B-Cell1
0TerminatedTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Therapy-Related Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAutologous Hematopoietic Stem Cell Transplant Recipient / Leukemia, Plasma Cell / Loss of Chromosome 17p / Recurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma1
1Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentPlasma Cell Myeloma1
1Active Not RecruitingTreatmentRecurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma1
1Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1Active Not RecruitingTreatmentTumors, Solid / Urethral Cancer1
1CompletedBasic ScienceAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)1
1CompletedOtherMultiple Myeloma (MM)1
1CompletedOtherNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedPreventionHematopoetic Stem Cell Transplant1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia (AML) / Chronic Chronic myelogenous leukemia / Myelodysplastic Syndrome1
1CompletedTreatmentAcute Myeloid Leukemia (AML)1
1CompletedTreatmentAcute Myeloid Leukemia (AML) / Acute Myeloid Leukemia With Multilineage Dysplasia Following / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Myelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
1CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Blastic Phase / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Disease / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Promyelocytic Leukemia (M3) / Blastic Phase Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia1
1CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Anaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Post Transplant Lymphoproliferative Disorder / Primary Central Nervous System Hodgkin Lymphoma / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Leukemia, Prolymphocytic / Peripheral T-Cell Lymphoma (PTCL) / Post Transplant Lymphoproliferative Disorder / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Small Intestine Lymphoma / T-Cell Large Granular Lymphocyte Leukemia1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Malignancy / Malignant Lymphomas / Plasma Cell Myeloma / Tumors, Solid1
1CompletedTreatmentAdvanced or Metastatic Solid Tumors1
1CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Childhood Acute Promyelocytic Leukemia (M3) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1CompletedTreatmentBrain Cancer / Central Nervous System Neoplasms / Cervix Cancer / Head and Neck Carcinoma1
1CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Metastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Melanoma of Skin / Malignant Neoplasm of Pancreas / Melanoma (Skin) / Ovarian Cancer / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBreast Cancer / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Ovarian Cancer / Prostate Cancer / Renal Cancers / Sarcomas1
1CompletedTreatmentBreast Cancer / Colorectal Cancers / Head and Neck Carcinoma / Lung Cancers / Malignant Neoplasm of Pancreas / Renal Cancers / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Advanced2
1CompletedTreatmentCarcinoid Tumors / Melanoma / Parathyroid Carcinoma / Small Cell Lung Cancer (SCLC) / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentCarcinoma Breast Stage IV1
1CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Medulloepithelioma / Childhood Meningioma / Childhood Mixed Glioma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Childhood Oligodendroglioma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hematopoietic/Lymphoid Cancer / Nodal marginal zone B-cell lymphomas / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Refractory Multiple Myeloma / Stage III Multiple Myeloma / Stage IV Chronic Lymphocytic Leukemia / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers2
1CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
1CompletedTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Plasma Cell Myeloma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cancer1
1CompletedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentGlioblastoma Multiforme (GBM)1
1CompletedTreatmentGraft Versus Host Disease (GVHD) / Peripheral Blood Stem Cell Transplantation / Transplantation, Homologous1
1CompletedTreatmentHead and Neck Carcinoma1
1CompletedTreatmentCarcinoma squamous / Head and Neck Carcinoma / Laryngeal Cancer / Oral Cancers / Pharyngeal Cancer / Squamous Carcinoma1
1CompletedTreatmentHepatic Complications / Neoplasms, Malignant1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma1
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Mature T-cell and Nk-cell Neoplasms / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes (MDS) / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentMalignancies, Hematologic1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMalignant Lymphomas / Neuroblastomas / Sarcomas / WilmsTumor1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Pleural Effusions / Non-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentMantle Cell Lymphoma (MCL)1
1CompletedTreatmentMelanoma2
1CompletedTreatmentMultiple Myeloma (MM)19
1CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
1CompletedTreatmentMultiple Myeloma, Plasma Cell Leukemia1
1CompletedTreatmentMyelodysplasia1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Tumors1
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Plasma Cell Myeloma1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed/Refractory Multiple Myeloma1
1CompletedTreatmentSquamous Cell Carcinoma (SCC)1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific9
1CompletedTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1Not Yet RecruitingOtherRelapsed and/or Refractory Multiple Myeloma1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Acute Lymphoblastic Leukaemia Recurrent / Acute, recurrent Myeloid Leukemia / Anatomic Stage IV Breast Cancer AJCC v8 / Anemia / Ann Arbor Stage III Hodgkin Lymphoma / Ann Arbor Stage III Non-Hodgkin Lymphoma / Ann Arbor Stage IIIA Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IV Non-Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Castration-Resistant Prostate Carcinoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic, recurrent Lymphocytic Leukemia / Hematopoietic and Lymphoid Cell Neoplasm / Locally Advanced Pancreatic Adenocarcinoma / Metastatic Breast Carcinoma / Metastatic Malignant Solid Neoplasm / Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Pancreatic Adenocarcinoma Metastatic / Primary Myelofibrosis / Prognostic Stage IV Breast Cancer AJCC v8 / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Recurrent Hematologic Malignancy / Recurrent Hodgkin Lymphoma / Recurrent Myelodysplastic Syndrome / Recurrent Myelodysplastic/Myeloproliferative Neoplasm / Recurrent Myeloproliferative Neoplasm / Recurrent Non-Hodgkin Lymphoma / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Acute Lymphoblastic Leukemia / Refractory Acute Myelogenous Leukemia (AML) / Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Refractory Chronic Myelomonocytic Leukemia / Refractory Hematologic Malignancy / Refractory Hodgkin Lymphoma / Refractory Malignant Solid Neoplasm / Refractory Myelodysplastic Syndrome / Refractory Myelodysplastic/Myeloproliferative Neoplasm / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Primary Myelofibrosis / Refractory Small Lymphocytic Lymphoma / Stage II Pancreatic Cancer AJCC v8 / Stage IIA Pancreatic Cancer AJCC v8 / Stage IIB Pancreatic Cancer AJCC v8 / Stage III Pancreatic Cancer AJCC v8 / Stage IV Pancreatic Cancer AJCC v8 / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v8 / Unresectable Pancreatic Adenocarcinoma1
1RecruitingTreatmentAcute Lymphoblastic Leukemia With Failed Remission / Acute Lymphoblastic Leukemia, in Relapse1
1RecruitingTreatmentCarcinoma, Non-Small -Cell Lung / Chronic Myeloid Leukemia (CML) / Colon/ Rectal Ca / Multiple Myeloma (MM) / Non-Small Cell Lung Carcinoma (NSCLC) / Pancreatic Ca1
1RecruitingTreatmentDysferlinopathy1
1RecruitingTreatmentMalignant Lymphomas / Myelodysplastic Syndromes (MDS) / Neoplasms1
1RecruitingTreatmentMalignant Lymphomas / Relapsed/Refractory T-cell Lymphomas1
1RecruitingTreatmentMultiple Myeloma (MM)2
1RecruitingTreatmentMultiple Myeloma (MM) / Novel Coronavirus Infectious Disease (COVID-19)1
1RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1SuspendedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatment714leukemia / Malignant Lymphomas1
1TerminatedTreatmentAdult Grade III Lymphomatoid Granulomatosis / AIDS-related Peripheral/Systemic Lymphoma / Anaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Waldenström's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Anaplastic Large-Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Chronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
1TerminatedTreatmentAdult Non-Hodgkin's Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma1
1TerminatedTreatmentAdvanced Non Small Cell Lung Cancer / Other Solid Tumors1
1TerminatedTreatmentAdvanced Solid Tumors1
1TerminatedTreatmentDisorders, Lymphoproliferative / Malignant Lymphomas1
1TerminatedTreatmentLung Cancers1
1TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentMantle Cell Lymphoma (MCL)1
1TerminatedTreatmentMultiple Myeloma (MM)4
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentMyelodysplastic Syndrome1
1TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentMultiple Myeloma (MM)1
1Unknown StatusTreatmentRefractory Autoimmune Cytopenia(s)1
1WithdrawnTreatmentLeukemia, Plasma Cell1
1WithdrawnTreatmentMultiple Myeloma (MM)1
1WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma1
1WithdrawnTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingPreventionHaematological Malignancies1
1, 2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)3
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)4
1, 2Active Not RecruitingTreatmentNeurotoxicity Syndrome / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentRecurrent Neuroblastoma1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
1, 2CompletedPreventionMalignancies, Hematologic1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Myeloid Leukemia (AML)2
1, 2CompletedTreatmentAcute Myeloid Leukemia (AML) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentBreast Cancer / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Ovarian Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentKidney Transplant Rejection1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas1
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL)2
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)11
1, 2CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Refractory / Relapses1
1, 2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Peripheral T-Cell Lymphoma (PTCL)1
1, 2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer1
1, 2CompletedTreatmentPlasma Cell Myeloma2
1, 2CompletedTreatmentProstatic Neoplasms1
1, 2CompletedTreatmentAcute, relapsed Leukemia / Refractory Acute Leukemia1
1, 2CompletedTreatmentRefractory Multiple Myeloma2
1, 2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2Not Yet RecruitingTreatmentCancer of Colon / Cancer of Liver / Cancer of Pancreas / Cancer of Rectum / Cancer of the Gallbladder / Glioblastoma Multiforme (GBM) / Multiple Myeloma (MM)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
1, 2RecruitingTreatmentGlioblastomas1
1, 2RecruitingTreatmentMultiple Myeloma (MM)4
1, 2RecruitingTreatmentTransplants and Implants1
1, 2RecruitingTreatmentTreatments1
1, 2TerminatedTreatmentAdvanced Malignancies / Metastatic Cancers / Tumors, Solid1
1, 2TerminatedTreatmentBrain and Central Nervous System Tumors / Melanoma / Tumors, Solid1
1, 2TerminatedTreatmentColorectal Cancers1
1, 2TerminatedTreatmentFollicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL)1
1, 2TerminatedTreatmentMalignancies / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentMalignant Lymphomas2
1, 2TerminatedTreatmentMedullary Thyroid Cancer (MTC)1
1, 2TerminatedTreatmentMultiple Myeloma (MM)5
1, 2TerminatedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2TerminatedTreatmentPlasma Cell Myeloma / Plasmacytosis / Recurrent Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)2
1, 2Unknown StatusTreatmentMultiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation1
1, 2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Unknown StatusTreatmentMyelodysplastic Syndromes (MDS)1
1, 2Unknown StatusTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1, 2Unknown StatusTreatmentRecurrent Mantle Cell Lymphoma1
1, 2Unknown StatusTreatmentTransplantation, Renal / Uremia1
1, 2WithdrawnTreatmentLung Cancers2
1, 2WithdrawnTreatmentMultiple Myeloma (MM)2
1, 2WithdrawnTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma1
1, 2WithdrawnTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingSupportive CareMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Therapy-Related Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAmyloidosis1
2Active Not RecruitingTreatmentAnn Arbor Stage III Grade 1 Follicular Lymphoma / Ann Arbor Stage III Grade 2 Follicular Lymphoma / Ann Arbor Stage III Grade 3 Follicular Lymphoma / Ann Arbor Stage IV Grade 1 Follicular Lymphoma / Ann Arbor Stage IV Grade 2 Follicular Lymphoma / Ann Arbor Stage IV Grade 3 Follicular Lymphoma / Grade 3a Follicular Lymphoma1
2Active Not RecruitingTreatmentChronic Antibody-mediated Transplant Rejection1
2Active Not RecruitingTreatmentChronic Graft Versus Host Disease1
2Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / Multiple Myeloma (MM)1
2Active Not RecruitingTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentEstrogen Receptor Positive / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentHigh-Risk Cancer / Multiple Myeloma (MM)1
2Active Not RecruitingTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMalignant Lymphomas / Neurologic toxicity / Therapy-Related Toxicity1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2Active Not RecruitingTreatmentMultiple Myeloma (MM)19
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)3
2CompletedPreventionChronic Chronic myelogenous leukemia / Chronic Lymphocytic Leukaemia (CLL) / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma (FL) / Leukemia, Acute / Lymphoma, B-Cell / Lymphoma, Hodgkins / Myelodysplasia / Small Lymphocytic Lymphoma1
2CompletedPreventionMultiple Myeloma (MM)1
2CompletedTreatmentAdenocarcinoma of the Extrahepatic Bile Duct / Adenocarcinoma of the Gallbladder / Advanced Adult Primary Liver Cancer / Gastrointestinal Cancers / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer / Recurrent Extrahepatic Bile Duct Cancer / Recurrent Gallbladder Cancer / Unresectable Extrahepatic Bile Duct Cancer / Unresectable Gallbladder Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Malignant Pleural Effusions / Non-Small Cell Lung Cancer Recurrent / Squamous Cell Carcinoma of Lung / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Non-Small Cell Lung Cancer Recurrent / Non-Small Cell Lung Carcinoma (NSCLC) / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Gastric Cancer / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Gastric Cancer / Stage IIIB Gastric Cancer / Stage IIIC Gastric Cancer1
2CompletedTreatmentAdult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
2CompletedTreatmentAdult Diffuse Large B-Cell Lymphoma / B-Cell Non-Hodgkin Lymphomas(NHL) / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Lymphocyte Predominant Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer2
2CompletedTreatmentAdvanced Solid Tumors1
2CompletedTreatmentAllogeneic Stem Cell Transplantation / Refractory Autoimmune Cytopenia(s)1
2CompletedTreatmentAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / Angioimmunoblastic T-Cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Extranodal NK/T-cell Lymphoma Nasal Type / Extranodal NK/T-cell Lymphoma, Nasal Type / Hepatosplenic T-Cell Lymphoma / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant1
2CompletedTreatmentAntibody-mediated Rejection / Late Rejection of Renal Transplant1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Adult Acute Lymphoblastic Leukemia (ALL) / Ph Positive Adult Acute Lymphoblastic Leukemia / Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia (ALL) / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia (ALL)1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBrain and Central Nervous System Tumors2
2CompletedTreatmentBreast Cancer1
2CompletedTreatmentCD20 Positive / Hematopoietic and Lymphoid Cell Neoplasm / Lymphocytic Neoplasm / Malignant Lymphomas1
2CompletedTreatmentCancer, Bladder / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor1
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentCarcinoma, Colorectal1
2CompletedTreatmentChronic Graft Versus Host Disease1
2CompletedTreatmentChronic Lymphocytic Leukemia (CLL) - Refractory / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentCiliary Body and Choroid Melanoma, Medium/Large Size / Extraocular Extension Melanoma / Iris Melanoma / Recurrent Intraocular Melanoma / Recurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
2CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)2
2CompletedTreatmentDuct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
2CompletedTreatmentEpstein Barr Virus Infections / Epstein-Barr Virus Infections / Post-transplant Lymphoproliferative Disease (PTLD) / Solid Organ Transplant / Stem Cell Transplant (Bone Marrow Transplant)1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentFollicular Lymphoma (FL)2
2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell / Marginal Lymphoma1
2CompletedTreatmentGlioblastomas / Gliosarcoma1
2CompletedTreatmentGliomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentIndolent Lymphoma / Malignant Lymphomas / Mantle Cell Lymphoma (MCL) / Small Lymphocytic Lymphoma1
2CompletedTreatmentInsular Thyroid Cancer / Recurrent Thyroid Cancer / Stage II Follicular Thyroid Cancer / Stage II Papillary Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer1
2CompletedTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2CompletedTreatmentLeukemias2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2CompletedTreatmentLung Cancers2
2CompletedTreatmentLymphoma, B Cell / Lymphoma, B-Cell1
2CompletedTreatmentLymphoma, B-Cell2
2CompletedTreatmentLymphoma, Mucosa-Associated Lymphoid Tissue1
2CompletedTreatmentLymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentMALT Lymphoma1
2CompletedTreatmentMalignant Lymphomas13
2CompletedTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentMantle Cell Lymphoma (MCL)2
2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMesothelioma, Malignant2
2CompletedTreatmentMetastatic Bladder Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Stage III Bladder Cancer / Stage III Urethral Cancer / Stage IV Urethral Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer1
2CompletedTreatmentMetastatic / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMultiple Myeloma (MM)55
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm6
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm / Neurologic toxicity1
2CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
2CompletedTreatmentMyelodysplastic Syndromes (MDS)1
2CompletedTreatmentNeuromyelitis Optica Spectrum Disorder1
2CompletedTreatmentNon Hodgkin's Follicular Lymphoma1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC) / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)4
2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Non-Small Cell Lung Carcinoma (NSCLC) / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)3
2CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2CompletedTreatmentPrimary Systemic Amyloidosis1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentProstate Neoplasms1
2CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Salivary Gland Adenoid Cystic Carcinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer1
2CompletedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Non-Hodgkin Lymphoma1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentRecurrent Classic Hodgkin Lymphoma / Refractory Classic Hodgkin Lymphoma1
2CompletedTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
2CompletedTreatmentRecurrent Mantle Cell Lymphoma1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Nasopharyngeal Cancer / Stage IV Nasopharyngeal Cancer1
2CompletedTreatmentRecurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2CompletedTreatmentRefractory Cold Agglutinin Disease1
2CompletedTreatmentRefractory Plasma Cell Myeloma1
2CompletedTreatmentRejection, Transplant1
2CompletedTreatmentRelapse/Refractory Multiple Myeloma1
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentRenal Cancers3
2CompletedTreatmentSarcomas1
2CompletedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma3
2CompletedTreatmentTransplant, Kidney / Transplantation, Kidney1
2CompletedTreatmentWaldenström's Macroglobulinemia (WM)4
2No Longer AvailableNot AvailableMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentAcquired Pure Red Cell Aplasia1
2Not Yet RecruitingTreatmentHigh Risk / Newly Diagnosed / Plasma Cell Myeloma1
2Not Yet RecruitingTreatmentImmune Thrombocytopenia1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)3
2Not Yet RecruitingTreatmentRefractory Multiple Myeloma1
2RecruitingBasic ScienceDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingSupportive CareMultiple Myeloma (MM)1
2RecruitingTreatmentAcquired Hemophilia A1
2RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Burkitt's Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Burkitt Leukemia / Recurrent Burkitt Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Refractory Acute Lymphoblastic Leukemia / Refractory Burkitt Leukemia / Refractory Burkitt Lymphoma / Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2RecruitingTreatmentAcute Lymphoblastic Leukemia, in Relapse1
2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAdult-onset Immunodeficiency1
2RecruitingTreatmentAutoimmune Encephalitis1
2RecruitingTreatmentAutoimmune Hemolytic Anemia / Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentDisorders, Lymphoproliferative / HHV-8 / Human Immunodeficiency Virus (HIV) Infections / Malignancies1
2RecruitingTreatmentExtramedullary Plasmacytoma / Multiple Myeloma (MM)1
2RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentHaematological Malignancies1
2RecruitingTreatmentHigh Grade Serous Carcinoma / Ovarian Neoplasm Epithelial1
2RecruitingTreatmentIdiopathic Multicentric Castleman's Disease1
2RecruitingTreatmentInterstitial Lung Diseases (ILD) / Scleroderma / Sclerosis, Progressive Systemic1
2RecruitingTreatmentLight Chain (AL) Amyloidosis, Stage 3B1
2RecruitingTreatmentLymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2RecruitingTreatmentMarginal Zone Lymphoma (MZL)1
2RecruitingTreatmentMultiple Myeloma (MM)10
2RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma2
2RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL) / Peripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentPlasma Cell Myeloma / Renal Failure1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentRefractory Multiple Myeloma1
2RecruitingTreatmentRelapsed Acute Promyelocytic Leukemia1
2RecruitingTreatmentRelapsed and/or Refractory Cutaneous T-cell Lymphoma1
2RecruitingTreatmentWaldenström's Macroglobulinemia (WM)2
2TerminatedPreventionAgnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukemia, Acute / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Small Lymphocytic Lymphoma1
2TerminatedPreventionDisorder of Transplanted Kidney1
2TerminatedPreventionGraft Versus Host Disease (GVHD)1
2TerminatedPreventionMalignancies / Multiple Myeloma (MM) / Plasma Cell Myeloma1
2TerminatedPreventionMultiple Myeloma (MM)1
2TerminatedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Stage IV Pancreatic Cancer1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukemia (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia (Secondary AML, sAML)1
2TerminatedTreatmentAdenocarcinoma, Bronchiolo-Alveolar / Non-Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentBronchiolitis Obliterans (BO)1
2TerminatedTreatmentCardiac Transplant / Heart Transplantation / Primary Heart Transplant1
2TerminatedTreatmentCervical Cancers1
2TerminatedTreatmentDisorders, Lymphoproliferative1
2TerminatedTreatmentExtranodal NK-T-CELL LYMPHOMA1
2TerminatedTreatmentFollicular Lymphoma (FL)4
2TerminatedTreatmentHeart Transplantation1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Mantle Cell Lymphoma (MCL)1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndrome1
2TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Mucosa-Associated Lymphoid Tissue1
2TerminatedTreatmentMDS1
2TerminatedTreatmentMalignant Lymphomas3
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentMantle Cell Lymphoma (MCL)1
2TerminatedTreatmentMetastatic Breast Cancer1
2TerminatedTreatmentMetastatic Renal Cell Carcinoma1
2TerminatedTreatmentMultiple Myeloma (MM)17
2TerminatedTreatmentMyasthenia Gravis / Rheumatoid Arthritis / Systemic Lupus Erythematosus (SLE)1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2TerminatedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
2TerminatedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
2TerminatedTreatmentRefractory Multiple Myeloma1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentStage IIIB or IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1
2Unknown StatusTreatmentAcute Myeloid Leukemia (AML)1
2Unknown StatusTreatmentBortezomib / Cyclophosphamide / Dexamethasone / Granulocyte Colony-Stimulating Factor / Plasma Cell Myeloma1
2Unknown StatusTreatmentEnd Stage Renal Disease (ESRD)1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentMantle Cell Lymphoma (MCL)1
2Unknown StatusTreatmentMesothelioma1
2Unknown StatusTreatmentMultiple Myeloma (MM)6
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2Unknown StatusTreatmentWaldenström's Macroglobulinemia (WM)1
2WithdrawnPreventionMultiple Myeloma (MM)1
2WithdrawnTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
2WithdrawnTreatmentAmyloidosis / Immunoglobulin Light Chain Deposition1
2WithdrawnTreatmentHigh Grade B-Cell Lymphoma, Not Otherwise Specified / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / Refractory Burkitt Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements1
2WithdrawnTreatmentMalignancies1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentMantle Cell Lymphoma (MCL)1
2WithdrawnTreatmentMultiple Myeloma (MM)5
2WithdrawnTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse1
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNasopharyngeal Carcinoma1
2WithdrawnTreatmentNon-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentOvarian Cancer1
2WithdrawnTreatmentPlasma Cell Myeloma1
2WithdrawnTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2, 3CompletedTreatmentMultiple Myeloma (MM)2
2, 3Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3TerminatedTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Granulocytic Sarcoma / Leukaemia cutis / Myeloid Neoplasm1
3Active Not RecruitingTreatmentAdult T Acute Lymphoblastic Leukemia / Ann Arbor Stage II Adult Lymphoblastic Lymphoma / Ann Arbor Stage II Childhood Lymphoblastic Lymphoma / Ann Arbor Stage III Adult Lymphoblastic Lymphoma / Ann Arbor Stage III Childhood Lymphoblastic Lymphoma / Ann Arbor Stage IV Adult Lymphoblastic Lymphoma / Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma / Childhood T Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAmyloidosis1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)2
3Active Not RecruitingTreatmentMultiple Myeloma (MM)15
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentPreviously Untreated Symptomatic Multiple Myeloma1
3Active Not RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
3CompletedNot AvailableMultiple Myeloma (MM)1
3CompletedDiagnosticMultiple Myeloma (MM)1
3CompletedTreatmentAmyloidosis1
3CompletedTreatmentChronic Renal Failure With Uremic Nephropathy1
3CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
3CompletedTreatmentEffects of Chemotherapy / Multiple Myeloma (MM)1
3CompletedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
3CompletedTreatmentMultiple Myeloma (MM)29
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPlasma Cell Myeloma1
3No Longer AvailableNot AvailableMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentIdiopathic Thrombocytopenic Purpura / Immune Thrombocytopenia1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAuto Stem Cell Transplant / Multiple Myeloma (MM)1
3RecruitingTreatmentIntrahepatic Cholangiocarcinoma1
3RecruitingTreatmentMultiple Myeloma (MM)8
3RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
3RecruitingTreatmentPlasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3SuspendedTreatmentRelapsed/Refractory Multiple Myeloma1
3TerminatedTreatmentAL Amyloidosis1
3TerminatedTreatmentMultiple Myeloma (MM)5
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Unknown StatusTreatmentExtramedullary Plasmacytoma1
3Unknown StatusTreatmentMultiple Myeloma (MM)3
3Unknown StatusTreatmentTransplantation, Kidney1
3WithdrawnTreatmentMalignant Lymphomas1
3WithdrawnTreatmentMultiple Myeloma (MM)1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)1
4Active Not RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
4CompletedNot AvailableHematological Neoplasms / Multiple Myeloma (MM)2
4CompletedNot AvailableMultiple Myeloma (MM)7
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentChronic Kidney Disease (CKD) / IgA Nephropathy1
4CompletedTreatmentHLA Sensitization1
4CompletedTreatmentMultiple Myeloma (MM)3
4RecruitingTreatmentHematological Neoplasms1
4RecruitingTreatmentMultiple Myeloma (MM)1
4RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
4RecruitingTreatmentPatients Awaiting a Living Kidney Donation1
4RecruitingTreatmentPompe's Disease1
4RecruitingTreatmentWaldenström's Macroglobulinemia (WM)1
4TerminatedTreatmentMultiple Myeloma (MM)1
4Unknown StatusTreatmentMultiple Myeloma (MM)1
4WithdrawnTreatmentHematuria / Nephritis, Lupus / Proteinuria1
Not AvailableActive Not RecruitingNot AvailableMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Small Lymphocytic Lymphoma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Untreated Hairy Cell Leukemia / Waldenström's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAmyloidosis; Systemic1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableAmyloidosis1
Not AvailableCompletedNot AvailableCardiotoxins / Heart Failure, Systolic / Multiple Myeloma (MM)1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM)2
Not AvailableCompletedTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
Not AvailableCompletedTreatmentAmyloidosis1
Not AvailableCompletedTreatmentAmyloidosis / Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) / Light Chain Deposition Disease (LCDD or MIDD) / Monoclonal Immunoglobulin Deposition Disease (MIDD)1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableRecruitingNot AvailableChemotherapy Induced Peripheral Neuropathy (CIPN) / Multiple Myeloma (MM)1
Not AvailableRecruitingTreatmentAntibody-mediated Rejection1
Not AvailableRecruitingTreatmentChildhood Acute Lymphoblastic Leukemia1
Not AvailableTerminatedTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas / Marginal Zone Lymphoma (MZL)1
Not AvailableTerminatedTreatmentSickle Cell Anemia / Sickle Cell-hemoglobin C Disease / Sickle Cell-β0-thalassemia1

Pharmacoeconomics

Manufacturers
  • Millennium pharmaceuticals inc
Packagers
  • Ben Venue Laboratories Inc.
  • Janssen-Ortho Inc.
  • Millennium Pharmaceuticals
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous1 mg/1mL
Injection, powder, lyophilized, for solutionIntravenous3.5 mg/1
Injection, powder, for solutionIntravenous; Subcutaneous3.5 mg
Powder, for solutionIntravenous
Powder, for solutionIntravenous; Subcutaneous
Injection, powder, for solutionIntravenous1.0 mg
Injection, powder, lyophilized, for solutionIntravenous; Subcutaneous3.5 mg/1
Powder, for solutionIntravenous; Subcutaneous3.5 mg
Prices
Unit descriptionCostUnit
Velcade 3.5 mg vial1590.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6083903No2000-07-042014-10-28Us
CA2203936No2005-04-122015-10-27Canada
US5780454Yes1998-07-142017-11-03Us
US6958319Yes2005-10-252022-07-25Us
US6713446Yes2004-03-302022-07-25Us
US8962572No2015-02-242032-11-03Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)139-143Thermo Fisher Scientific Bortezomib Safety Data Sheet
water solubilityThe solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5.Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0532 mg/mLALOGPS
logP0.89ALOGPS
logP1.53ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)13.04ChemAxon
pKa (Strongest Basic)-0.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area124.44 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity99.37 m3·mol-1ChemAxon
Polarizability40.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.6935
Blood Brain Barrier-0.6533
Caco-2 permeable-0.6576
P-glycoprotein substrateSubstrate0.5909
P-glycoprotein inhibitor INon-inhibitor0.785
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9445
CYP450 2C9 substrateNon-substrate0.7145
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5209
CYP450 1A2 substrateNon-inhibitor0.855
CYP450 2C9 inhibitorNon-inhibitor0.8267
CYP450 2D6 inhibitorNon-inhibitor0.9304
CYP450 2C19 inhibitorNon-inhibitor0.8108
CYP450 3A4 inhibitorNon-inhibitor0.7308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9604
Ames testNon AMES toxic0.7439
CarcinogenicityNon-carcinogens0.8064
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.4537 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9936
hERG inhibition (predictor II)Non-inhibitor0.8593
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0035900000-122163b342b985220f63
MS/MS Spectrum - , positiveLC-MS/MSsplash10-016r-1397000000-e168634cfe7e1453d742

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylalanine and derivatives. These are compounds containing phenylalanine or a derivative thereof resulting from reaction of phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Phenylalanine and derivatives
Alternative Parents
N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / Amphetamines and derivatives / Pyrazinecarboxamides / 2-heteroaryl carboxamides / Fatty amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Boronic acids / Organic metalloid salts
show 7 more
Substituents
Phenylalanine or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Amphetamine or derivatives / Pyrazine carboxylic acid or derivatives / Pyrazinecarboxamide / 2-heteroaryl carboxamide / Monocyclic benzene moiety / Fatty amide / Pyrazine
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazines, amino acid amide, L-phenylalanine derivative (CHEBI:52717)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Threonine-type endopeptidase activity
Specific Function
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly ...
Gene Name
PSMB5
Uniprot ID
P28074
Uniprot Name
Proteasome subunit beta type-5
Molecular Weight
28480.01 Da
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Threonine-type endopeptidase activity
Specific Function
The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly ...
Gene Name
PSMB1
Uniprot ID
P20618
Uniprot Name
Proteasome subunit beta type-1
Molecular Weight
26489.09 Da

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Curator comments
There is no time-dependent inhibition of CYP3A4 by bortezomib or its metabolites (Lu et al., 2006).
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Hellmann A, Rule S, Walewski J, Shpilberg O, Feng H, van de Velde H, Patel H, Skee DM, Girgis S, Louw VJ: Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. Clin Pharmacokinet. 2011 Dec 1;50(12):781-91. doi: 10.2165/11594410-000000000-00000. [PubMed:22087865]
  2. Zhou W, An G, Jian Y, Guo H, Chen W: Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma. Oncol Lett. 2015 Aug;10(2):1171-1175. doi: 10.3892/ol.2015.3294. Epub 2015 May 29. [PubMed:26622646]
  3. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
  4. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8. doi: 10.1124/dmd.105.008060. Epub 2006 Jan 27. [PubMed:16443666]
  5. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
Curator comments
In an in vitro study, bortezomib and its metabolites M1 and M2 were found to be mild inhibitors of CYP2C19 with IC50 values of approximately 18.0, 10.0, and 13.2 microM, respectively (Lu et al., 2006).
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
  3. Uttamsingh V, Lu C, Miwa G, Gan LS: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8. doi: 10.1124/dmd.105.005710. Epub 2005 Aug 15. [PubMed:16103134]
  4. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8. doi: 10.1124/dmd.105.008060. Epub 2006 Jan 27. [PubMed:16443666]
  5. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Uttamsingh V, Lu C, Miwa G, Gan LS: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8. doi: 10.1124/dmd.105.005710. Epub 2005 Aug 15. [PubMed:16103134]
  3. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
  4. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
  2. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
Inhibitor
Curator comments
In an in vitro study, the M1 metabolite of bortezomib was a mild inhibitor of CYP2C9 with an IC50 value of approximately 11.5 microM (Lu et al., 2006).
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G: Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. doi: 10.1124/dmd.104.002956. Epub 2005 Mar 11. [PubMed:15764713]
  2. Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS: Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8. doi: 10.1124/dmd.105.008060. Epub 2006 Jan 27. [PubMed:16443666]
  3. Uttamsingh V, Lu C, Miwa G, Gan LS: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8. doi: 10.1124/dmd.105.005710. Epub 2005 Aug 15. [PubMed:16103134]
  4. FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use [Link]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P: The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. doi: 10.1007/s00280-013-2136-7. Epub 2013 Apr 16. [PubMed:23589314]
  2. Clemens J, Welti L, Schafer J, Seckinger A, Burhenne J, Theile D, Weiss J: Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncol Lett. 2017 Sep;14(3):3185-3192. doi: 10.3892/ol.2017.6560. Epub 2017 Jul 8. [PubMed:28927064]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Alam K, Farasyn T, Crowe A, Ding K, Yue W: Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner. PLoS One. 2017 Nov 6;12(11):e0186924. doi: 10.1371/journal.pone.0186924. eCollection 2017. [PubMed:29107984]

Drug created on June 13, 2005 07:24 / Updated on July 11, 2020 00:05

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates